Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone and Acetaminophen for Acute Migraine
NCT06245902Phase 2Completed
- Sponsor
- Allodynic Therapeutics
- Start
- Feb 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of naltrexone and acetaminophen in migraine (5 arms), sponsored by Allodynic Therapeutics. Primary endpoints: Percentage of patients reporting no headache pain at 2 hours, Percentage of patients having absence of most bothersome migraine-associated symptom (MBS) at 2 hours and 1 more. Started Feb 2017; status: completed.
02
Drugs
naltrexoneacetaminophen
03
Conditions
migraine
Beyond the preview
Go deeper on NCT06245902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06245902.